Anatara Lifesciences Ltd (ASX:ANR)

Anatara Lifesciences Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	0.25	-	-	-	-	-
Cost of Revenue	1.32	0.75	1.6	0.75	0.84	1.29
Gross Profit	-1.07	-0.75	-1.6	-0.75	-0.84	-1.29
Selling, General & Admin	1.51	1.35	1.68	2.28	2.27	2.92
Other Operating Expenses	-0.64	-0.64	-1.24	-0.49	-1.07	-0.69
Operating Expenses	0.87	0.71	0.44	1.79	1.2	2.23
Operating Income	-1.94	-1.46	-2.05	-2.53	-2.04	-3.52
Interest Expense	-	-	-0	-0	-0	-
Interest & Investment Income	0.01	0.01	0.02	0.01	0.01	0.05
EBT Excluding Unusual Items	-1.93	-1.45	-2.03	-2.53	-2.03	-3.47
Other Unusual Items	-	-	0.01	-	0.04	0.1
Pretax Income	-1.93	-1.45	-2.02	-2.53	-2	-3.36
Net Income	-1.93	-1.45	-2.02	-2.53	-2	-3.36
Net Income to Common	-1.93	-1.45	-2.02	-2.53	-2	-3.36
Shares Outstanding (Basic)	185	150	98	71	63	50
Shares Outstanding (Diluted)	185	150	98	71	63	50
Shares Change (YoY)	52.75%	53.21%	37.65%	13.44%	26.25%	0.52%
EPS (Basic)	-0.01	-0.01	-0.02	-0.04	-0.03	-0.07
EPS (Diluted)	-0.01	-0.01	-0.02	-0.04	-0.03	-0.07
Free Cash Flow	-1.86	-1.25	-2.26	-2.24	-2.1	-2.73
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.03	-0.03	-0.06
Operating Margin	-775.12%	-	-	-	-	-
Profit Margin	-771.67%	-	-	-	-	-
Free Cash Flow Margin	-741.62%	-	-	-	-	-
EBITDA	-1.94	-1.46	-2.02	-2.51	-2.04	-3.5
D&A For EBITDA	0	0	0.02	0.02	0.01	0.02
EBIT	-1.94	-1.46	-2.05	-2.53	-2.04	-3.52

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.